MAPK-AP-1 Pathway Activity Determination via Target Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a clinical assay to accurately assess the functional state of the MAPK-AP-1 cellular signaling pathway, which is crucial for determining tumor-promoting activity and selecting appropriate therapeutic approaches, especially in cancers where abnormal MAPK-AP-1 signaling is involved.
Innovation Solution
A method and apparatus for determining the activity level of the MAPK-AP-1 cellular signaling pathway by calculating the activity level of an AP-1 transcription factor element using a calibrated pathway model that compares the expression levels of specific target genes, allowing for precise characterization of disease states and therapeutic decision-making.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional empirical treatment approaches are used for tumors, then treatment simplicity is maintained, but treatment precision and effectiveness deteriorate due to tumor heterogeneity
Solution Approach 1:
The patent segments the complex tumor diagnostic process into distinct molecular pathway assessments (MAPK-AP-1 pathway activity, gene expression profiles) that can be independently measured and integrated. This allows precise characterization of tumor heterogeneity through multiple discrete measurements rather than a single complex assay.
Solution Approach 2:
The patent introduces mathematical models and computational algorithms as intermediaries that translate raw gene expression data into clinically actionable pathway activity scores. These computational tools mediate between the complex molecular data and simple clinical decision-making, resolving the contradiction between measurement precision and diagnostic complexity.
2Measurement precision
If comprehensive molecular profiling is performed to assess tumor heterogeneity, then diagnostic accuracy improves, but time consumption and resource requirements increase
Solution Approach 1:
The patent extracts and focuses on specific key genes and pathways (MAPK-AP-1 signaling pathway components) that are most relevant to tumor characterization and treatment response. By selecting a targeted subset of molecular markers rather than profiling the entire transcriptome, the method achieves high diagnostic accuracy with reduced testing time and resources.
Solution Approach 2:
The patent performs preliminary selection and validation of target genes and pathways before clinical application. The mathematical models are pre-calibrated with reference data, allowing rapid assessment of pathway activity directly from clinical samples without requiring extensive preliminary processing or interpretation time.
3Adaptability or versatility
If pathway activity assessment methods are developed, then therapeutic decision-making improves, but method complexity and implementation difficulty increase
Solution Approach 1:
The patent transforms complex molecular data into simplified pathway activity parameters (normalized scores indicating pathway activation state). These standardized parameters can be directly interpreted by clinicians to guide therapeutic decisions, maintaining high therapeutic adaptability while simplifying the operational workflow through parameter standardization.
Data Source
AI summary
A bioinformatics process which provides an improved means to detect a MAPK-AP-1 cellular signaling pathway in a subject, such as a human, based on the expression levels of at least three unique target genes of the MAPK-AP-1 cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of MAPK-AP-1 cellular signaling pathway target genes.